PROSTATE ADENOCARCINOMA

This study tests a new type of radiation (SBRT) that targets only the tumor in the prostate, not the whole gland. The goal is to cure early-stage prostate cancer while reducing side effects like incontinence and impotence. About 42 men with low- or intermediate-risk cancer that h…

This study compares two modern treatments for men with low-to-intermediate risk prostate cancer that hasn't spread: a robotic partial prostatectomy (removing part of the prostate through a single port) and high-intensity focused ultrasound (HIFU), which uses sound waves to destro…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety and find the best dose. About 470 adults will take part to see if the drug can he…

This study compares two hormone-lowering drugs, Orgovyx and Eligard, in men with prostate cancer who are also getting radiation. The goal is to see which drug causes fewer heart problems. About 70 men will take one of the drugs for 6 months and have their heart function tested be…

This study looks at men whose prostate cancer has come back in a few spots after radiation therapy. It tests whether adding a hormone-blocking drug (ELIGARD) to targeted treatment helps keep the cancer from growing longer than targeted treatment alone. About 162 men will take par…

This study tests a radioactive drug (Lu-177-PSMA-617) given before surgery to men with high-risk prostate cancer. The goal is to see if the drug can shrink or eliminate the tumor, making surgery more effective. About 54 men with aggressive prostate cancer will receive the drug an…

This early-phase study tests a personalized approach to radiation therapy for men with high-risk prostate cancer. Doctors use special PET scans to see how the main tumor responds to hormone therapy, then adjust the timing and dose of radiation to better target it. The goal is to …

This study tests whether adding a drug called relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 men with advanced, localized prostate cancer that hasn't spread will take the combination for 24 weeks, the…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer treatment (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach is just as effective at preventing the cancer from …

This study tests whether adding two drugs (relugolix and enzalutamide) to radiation therapy can better control very-high-risk prostate cancer. Relugolix lowers testosterone that fuels cancer growth, while enzalutamide blocks cancer cell signals. The trial involves 50 participants…

This study is for people with high-risk prostate cancer that has spread to a few other spots. It tests whether giving less hormone therapy (based on each person's risk) along with radiation can control the cancer just as well as the standard longer hormone therapy. The goal is to…

This study tests whether a special 5-day-per-month diet that mimics fasting can improve how well standard prostate cancer treatments work. About 138 men with advanced prostate cancer that still responds to hormone therapy will either follow this diet or eat normally for 6 months.…

This study tests whether a daily supplement called urolithin A, found in pomegranates, can reduce cell damage in prostate tumors. About 90 men with prostate cancer will take either the supplement or a placebo for 3-6 weeks before their prostate removal surgery. The main goal is t…

This study tests whether adding a drug called apalutamide to standard hormone therapy and radiation can keep prostate cancer from spreading in people whose cancer was found in lymph nodes after prostate removal surgery. About 586 participants will be randomly assigned to get eith…

This study tests a new way to deliver radiation to prostate cancer that has spread to lymph nodes in the abdomen or pelvis. About 26 men whose cancer is otherwise controlled will receive a precise, adaptive type of radiation called SBRT, which targets both the tumor and nearby ly…

This early-stage study tests a small implant called Enolen that delivers the drug enzalutamide directly to prostate tumors in men scheduled for prostate removal surgery. The goal is to see if the implant is safe and can deliver the drug locally. About 56 men with prostate cancer …

This study tests whether giving the chemotherapy drug carboplatin before surgery can shrink tumors in men with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. About 44 participants will receive carboplatin before their prostate removal surgery. The goa…

This study tests a new treatment for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The treatment combines a hormone therapy (testosterone) with a radioactive drug (radium-223) to try to slow cancer growth. About 47 men will recei…

This study looks at whether personalized nutrition and exercise plans can help reduce frailty and improve body composition in prostate cancer survivors who are on hormone therapy (androgen deprivation therapy). About 50 participants will receive tailored advice and be monitored f…

This study is for men whose prostate cancer has come back (shown by rising PSA levels) after their prostate was removed. It tests whether using PET scans to guide more personalized treatment—adding the drug apalutamide with or without targeted radiation—works better than standard…

This study tests whether special PET/CT scans (PSMA or fluciclovine) can find small spots of prostate cancer that have spread beyond the prostate. By treating only those spots with targeted therapy, doctors hope to lower PSA levels and delay the need for long-term hormone therapy…

This study tests a new imaging agent called copper Cu 64 PSMA I&T, used with a PET/CT scan, to see if it can more accurately find cancer that has spread to lymph nodes in men with newly diagnosed, aggressive prostate cancer. About 439 men who are scheduled for prostate removal su…

This study tests whether taking a short course of hormone therapy (relugolix) before a PSMA PET/CT scan can make the scan better at finding prostate cancer that has spread. About 30 men with high-risk prostate cancer will get the hormone drug for 5, 10, or 15 days before their sc…

This study compares a new, personalized biopsy method that uses fewer needle samples to the standard method for diagnosing prostate cancer. The goal is to see if the new approach can find cancer just as well while causing less bleeding, pain, and infection. About 330 men with sus…

This study looks at whether adding a special PET/CT scan (rhPSMA-7.3) to the usual MRI can better find aggressive prostate cancer in men with low-risk cancer who are monitoring their disease. About 120 men will get both scans before a confirmatory biopsy. The goal is to see if th…

This study tests a computer program developed at the University of Chicago that creates risk maps from MRI scans of the prostate. The goal is to see if this tool helps doctors decide where to biopsy more accurately than current methods. About 180 adults with known or suspected pr…

This study tests a new technique called 'Spot Delete' in proton therapy for low- and intermediate-risk prostate cancer. The goal is to reduce side effects like diarrhea, rectal bleeding, and bladder problems by preventing proton beams from stopping in the bowel and rectum. The st…

This study is testing whether using a special dye called indocyanine green (ICG) during robot-assisted prostate removal surgery can help men recover bladder control and sexual function better. About 400 men with prostate cancer who are good candidates for nerve-sparing surgery wi…

This study tests if fezolinetant, a drug used for hot flashes in women, can reduce hot flashes in men with prostate cancer who are on hormone therapy. About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency, severity, and …

This study compares two different radiation schedules for men with low- or favorable-risk prostate cancer. The standard approach uses 5 treatments, while the experimental approach uses just 2. The goal is to see if the shorter course can maintain sexual quality of life just as we…

This study looks at two standard treatments for high-risk prostate cancer that hasn't spread: robot-assisted surgery and radiation therapy (often with hormone therapy). The goal is to see which one offers better quality of life, fewer side effects, and better cancer control. Abou…

This study follows 120 men with advanced prostate cancer to see if markers in their blood can predict how well they respond to hormone therapy. Researchers will collect blood samples and compare markers from those who respond well to those who don't. The goal is to develop a test…

This study looks at how hormonal therapy changes a protein called PSMA in prostate cancer cells, both in cancers that respond to hormone treatment and those that don't. Researchers will track 80 men with prostate cancer to see how PSMA levels change shortly after starting therapy…

This study is testing a special MRI scan that uses a substance called hyperpolarized pyruvate to see how well it can monitor prostate cancer in men who have chosen active surveillance (no immediate treatment). The goal is to see if this scan can detect changes in tumor cells more…

This study looks at whether offering cancer treatment at home instead of a hospital is practical and preferred by Black men with advanced prostate cancer. About 77 participants will share their thoughts on convenience, safety, and comfort. The goal is to reduce healthcare dispari…